Back to today’s briefing

Story perspectives

Abbott Labs Sees Strong Q1 Growth, Plans $500M Investment

4/16/2025

37 3

Summary

Story summary

Abbott Laboratories kicked off Q1 2025 with impressive earnings, boasting a 4% sales increase to $10.35 billion and an 11.2% rise in adjusted EPS to $1.09. Looking ahead, the company projects organic sales growth of 7.5-8.5% and adjusted EPS between $5.05 and $5.25, alongside a bold $500 million investment to tackle U.S. tariffs.

History

Historical Context

Abbott Laboratories' strong Q1 2025 earnings reflect a long-standing trend in the U.S. healthcare sector, where rising costs and competitive pressures have driven companies to innovate. This echoes Warren Buffett's 2010 critique of healthcare expenses, emphasizing the ongoing challenge of balancing quality care with economic viability.

1 of 2

Story summary

Abbott Laboratories kicked off Q1 2025 with impressive earnings, boasting a 4% sales increase to $10.35 billion and an 11.2% rise in adjusted EPS to $1.09. Looking ahead, the company projects organic sales growth of 7.5-8.5% and adjusted EPS between $5.05 and $5.25, alongside a bold $500 million investment to tackle U.S. tariffs.

1 / 2